(UroToday.com) In this session, Dr. Rana McKay discussed late-breaking abstract 5, results from the KEYNOTE-564 (KN-564) study of adjuvant pembrolizumab in resected clear-cell renal cell carcinoma (RCC).
(UroToday.com) In this session, Dr. Rana McKay discussed late-breaking abstract 5, results from the KEYNOTE-564 (KN-564) study of adjuvant pembrolizumab in resected clear-cell renal cell carcinoma (RCC).